• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Intravenous and oral administration of molsidomine, a pharmacodynamic and pharmacokinetic study.

作者信息

Bergstrand R, Vedin A, Wilhelmsson C, Peterson L E, Chamberlain J, Dell D, Stevens L A, Ostrowski J

出版信息

Eur J Clin Pharmacol. 1984;27(2):203-8. doi: 10.1007/BF00544046.

DOI:10.1007/BF00544046
PMID:6548711
Abstract

In 12 healthy male volunteers, molsidomine 1, 2 and 4 mg i.v. increased resting heart rate and decreased systolic blood pressure, the latter still being affected after 8 hours. After single oral doses of 1 and 2 mg, systolic pressure tended to be reduced for 90 minutes and exercise heart rate tended to be increased. After oral treatment with 2 mg molsidomine three times daily for 1 week, the pharmacokinetic parameters and the effects on heart rate and blood pressure after the final dose were not different from those after the first dose. The terminal half-life was independent of dose and route of administration. Clearance and distribution volume were not dose-dependent. The bioavailability of a 2 mg oral dose of molsidomine was 44%. Inter-individual variation in heart rate, blood pressure and pharmacokinetics was observed.

摘要

相似文献

1
Intravenous and oral administration of molsidomine, a pharmacodynamic and pharmacokinetic study.
Eur J Clin Pharmacol. 1984;27(2):203-8. doi: 10.1007/BF00544046.
2
Pharmacokinetics of molsidomine in humans.吗多明在人体中的药代动力学。
Am Heart J. 1985 Mar;109(3 Pt 2):641-3. doi: 10.1016/0002-8703(85)90670-2.
3
Hemodynamic effects of molsidomine, isosorbide dinitrate, and nifedipine at rest and during exercise.莫索尼定、硝酸异山梨酯和硝苯地平在静息及运动时的血流动力学效应。
Am Heart J. 1985 Mar;109(3 Pt 2):649-53. doi: 10.1016/0002-8703(85)90672-6.
4
Relationship between pharmacokinetics and pharmacodynamics of molsidomine and its metabolites in humans.莫西多明及其代谢产物在人体中的药代动力学与药效学之间的关系。
Am Heart J. 1985 Mar;109(3 Pt 2):644-8. doi: 10.1016/0002-8703(85)90671-4.
5
[Human pharmacokinetics of molsidomine].[莫西多明的人体药代动力学]
Ann Cardiol Angeiol (Paris). 1983 Dec;32(8):503-9.
6
Long-term effects of molsidomine on exercise tolerance in patients with exertional angina pectoris.莫西赛利对劳力性心绞痛患者运动耐量的长期影响。
Jpn Circ J. 1983 Dec;47(12):1398-405. doi: 10.1253/jcj.47.1398.
7
Clinical and hemodynamic effects of the new dilator drug molsidomine.
Am Heart J. 1985 Mar;109(3 Pt 2):674-7. doi: 10.1016/0002-8703(85)90679-9.
8
[Effect of molsidomine on hemodynamics and myocardial ischemia in patients with acute myocardial infarction (author's transl)].吗多明对急性心肌梗死患者血流动力学及心肌缺血的影响(作者译)
Klin Wochenschr. 1982 Jan 15;60(2):77-85. doi: 10.1007/BF01716385.
9
Pharmacokinetics of an extended-release dosage form of molsidomine in patients with coronary heart disease.冠心病患者中莫索尼定缓释剂型的药代动力学
Eur J Clin Pharmacol. 1985;28(5):611-3. doi: 10.1007/BF00544076.
10
Effectiveness of molsidomine in the long-term treatment of exertional angina pectoris and chronic congestive heart failure.莫西赛利在劳力型心绞痛和慢性充血性心力衰竭长期治疗中的疗效。
Am Heart J. 1985 Mar;109(3 Pt 2):670-4. doi: 10.1016/0002-8703(85)90678-7.

引用本文的文献

1
Clinical pharmacokinetics of drugs in patients with heart failure: an update (part 1, drugs administered intravenously).心力衰竭患者药物的临床药代动力学:更新(第 1 部分,静脉内给药的药物)。
Clin Pharmacokinet. 2013 Mar;52(3):169-85. doi: 10.1007/s40262-012-0029-2.
2
Clinical pharmacokinetics of vasodilators. Part II.血管扩张剂的临床药代动力学。第二部分。
Clin Pharmacokinet. 1998 Jul;35(1):9-36. doi: 10.2165/00003088-199835010-00002.
3
Clinical pharmacokinetics of molsidomine.莫西多明的临床药代动力学

本文引用的文献

1
Molsidomine in the treatment of patients with angina pectoris.莫西多明治疗心绞痛患者。
N Engl J Med. 1980 Jan 3;302(1):1-6. doi: 10.1056/NEJM198001033020101.
2
Comparative study of the haemodynamic effects of oral molsidomine and isosorbide dinitrate in man.口服吗多明与硝酸异山梨酯对人体血流动力学影响的比较研究。
Eur J Clin Pharmacol. 1982;23(1):11-4. doi: 10.1007/BF01061370.
3
Hemodynamic effects of molsidomine vasodilatory therapy in acute myocardial infarction.
Am Heart J. 1981 Apr;101(4):369-73. doi: 10.1016/0002-8703(81)90123-x.
Clin Pharmacokinet. 1996 May;30(5):372-84. doi: 10.2165/00003088-199630050-00004.
4
Pharmacokinetic profile of a novel slow release preparation of molsidomine.莫西多明新型缓释制剂的药代动力学特征
Eur J Clin Pharmacol. 1992;43(3):273-6. doi: 10.1007/BF02333022.
4
Double-blind controlled trial of molsidomine in hypertension.
Eur J Clin Pharmacol. 1980 Oct;18(3):231-5. doi: 10.1007/BF00563004.
5
[Molsidomine in ergometric tests (author's transl)].
Dtsch Med Wochenschr. 1980 Aug 29;105(35):1216-9. doi: 10.1055/s-2008-1070842.
6
[Molsidomin in coronary disease. Clinico-pharmacokinetic correlation study on the effect of oral and sublingual therapy].[莫西多明在冠状动脉疾病中的应用。口服和舌下含服治疗效果的临床药代动力学相关性研究]
MMW Munch Med Wochenschr. 1983 Feb 25;125(8):156-8.
7
Determination of molsidomine in plasma by high-performance liquid column chromatography.高效液相柱色谱法测定血浆中吗多明
J Chromatogr. 1978 Nov 1;146(3):465-73. doi: 10.1016/s0378-4347(00)81205-0.
8
Haemodynamic effects of molsidomin.
Eur J Clin Pharmacol. 1978 Jun 19;13(4):241-5. doi: 10.1007/BF00716357.
9
Acute double blind trial of a new anti-anginal drug: molsidomine.
Eur J Clin Pharmacol. 1978 Jun 19;13(4):247-50. doi: 10.1007/BF00716358.